Mar 12, 2025 · Clinical trials have shown it reduces abnormal blood vessel growth and leakage in the retina. This helps manage conditions like wet age-related macular degeneration (AMD), diabetic macular edema, and diabetic retinopathy. Eylea belongs to the drug class called Vascular Endothelial Growth Factor (VEGF) inhibitors.

Eylea has been shown to stop the growth of new abnormal blood vessels in the eye which often leak fluid or bleed. Eylea can help to stabilise, and in many cases, improve the vision loss related to wet AMD, CRVO, BRVO, DME and myopic CNV.

Mar 7, 2025 · Eylea 40mg/ml Injection is used for the treatment of eye diseases caused by diabetes, macular degeneration and macular swelling. It is administered directly into the eyeball by an eye specialist. It may cause temporary visual disturbances.

EYLEA is an FDA-approved, anti-VEGF, administered intravitreal injection to treat WET AMD, DME, MefRVO, and DR. Look here for more information about EYLEA. See Safety Information and full Prescribing Information.

The recommended dose for EYLEA is 0.4 mg (0.01 mL or 10 microliters of 40 mg/mL solution) administered by intravitreal injection. Treatment may be given bilaterally on the same day. Injections may be repeated in each eye. The treatment interval between doses injected into the same eye should be at least 10 days. (2.9)

EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) (1.1)

Eylea has been shown to stop the growth of new abnormal blood vessels in the eye which often leak fluid or bleed. Eylea can help to stabilise, and in many cases, improve the vision loss related to wet AMD, CRVO, BRVO, DME and myopic CNV.

1 mL solution for injection contains 40 mg aflibercept*. One vial contains an extractable volume of at least 0.1 mL, equivalent to at least 4 mg aflibercept. This provides a usable amount to deliver a single dose of 0.05 mL containing 2 mg aflibercept.

Feb 28, 2025 · Eylea is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), • visual impairment due to diabetic macular oedema (DME) (see section 5.1),

21 hours ago · Eylea is a brand-name injection doctors may prescribe for certain eye conditions. The medication is available in the following forms: single-dose vial and single-dose prefilled syringe. ... 2 milligrams (mg) per 0.05 milliliters (mL), also written as 40 mg/mL. Dosage for wet AMD. For treating wet AMD, the recommended Eylea dosage is 2 mg, given ...